A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with <i>IDH1</i>-Mutated Solid Tumors
Background: Mutations in isocitrate dehydrogenase 1 (<i>IDH1</i>) occur in 60% of chondrosarcoma, 80% of WHO grade II-IV glioma and 20% of intrahepatic cholangiocarcinoma. These solid <i>IDH1</i>-mutated tumors produce the oncometabolite <i>D</i>-2-hydroxyglutarat...
Main Authors: | Mohammed Khurshed, Remco J. Molenaar, Myra E. van Linde, Ron A. Mathôt, Eduard A. Struys, Tom van Wezel, Cornelis J. F. van Noorden, Heinz-Josef Klümpen, Judith V. M. G. Bovée, Johanna W. Wilmink |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/10/2474 |
Similar Items
-
Beyond the Influence of <i>IDH </i>Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
by: Sanne Venneker, et al.
Published: (2020-11-01) -
Research progress of IDH1 and IDH2 mutations in gliomas
by: Shan-shan ZHANG, et al.
Published: (2015-11-01) -
<i>IDH</i> Mutations in Glioma: Double-Edged Sword in Clinical Applications?
by: Alisan Kayabolen, et al.
Published: (2021-07-01) -
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
by: Claudio Cerchione, et al.
Published: (2021-03-01) -
IDH Mutation Analysis in Ewing Sarcoma Family Tumors
by: Ki Yong Na, et al.
Published: (2015-05-01)